All Trials

Phase II Study of Nab-sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with recurrent, histologically confirmed low-grade serous ovarian cancer (ECOG 0–1; measurable disease; prior MEK inhibitor allowed; ≤1 prior cytotoxic regimen; no prior mTOR/PI3K/AKT inhibitors) receive nab-sirolimus (albumin-bound mTOR inhibitor targeting PI3K/AKT/mTOR) IV plus fulvestrant (SERD) IM until progression or toxicity. Single-arm study with required pre-dose biopsy; key exclusions include significant cardiopulmonary disease, active uncontrolled infections, CNS disease needing recent steroids/RT, and strong CYP3A4 interactions.

ClinicalTrials.gov ID: NCT06494150

A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Maintenance combination of mirvetuximab soravtansine (FRα-targeted antibody–drug conjugate delivering DM4) plus olaparib (PARP inhibitor) for adult women with platinum-sensitive recurrent high-grade serous or endometrioid ovarian, primary peritoneal, or fallopian tube cancer who have CR/PR/SD after platinum and medium/high FRα expression (BRCA-mutated patients must have had prior PARP). Treatment continues until progression or toxicity; key exclusions include prior FRα-targeted therapy, CNS mets, significant ocular disease, and use of strong/moderate CYP3A modifiers.

ClinicalTrials.gov ID: NCT05887609

Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant high-grade serous ovarian cancer (progression within 6 months of last platinum; ECOG 0–1; any prior lines) receive oral atovaquone monotherapy. Atovaquone, an antiprotozoal repurposed here for its STAT3 pathway inhibition, is assessed for progression-free survival with correlative biopsies/ascites and imaging to evaluate on-target effects and immune microenvironment changes.

ClinicalTrials.gov ID: NCT05998135

Phase II Open-label, Multi-center Study of Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma (mUM) With Integrated Circulating Tumor DNA (ctDNA) Biomarker (TARGET-tebe)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: HLA-A*02:01–positive adults with previously untreated metastatic uveal melanoma receive weekly tebentafusp (step-up to 68 mcg), a bispecific gp100–HLA-directed ImmTAC that redirects T cells via anti-CD3 to melanoma cells. The trial integrates serial Signatera ctDNA monitoring to correlate early molecular response with clinical outcomes.

ClinicalTrials.gov ID: NCT06070012

A Phase I Study to Evaluate the Safety of Naltrexone and Propranolol in Combination With Standard of Care Ipilimumab and Nivolumab in Patients With Advanced Melanoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable stage III/IV melanoma eligible for ipilimumab 3 mg/kg plus nivolumab 1 mg/kg, ECOG 0–1, measurable disease, and no unstable brain mets or active autoimmune disease receive standard IPI+NIVO with propranolol (nonselective beta-adrenergic blocker) and escalating-dose naltrexone (opioid receptor antagonist) to test safety and define the recommended naltrexone dose. Prior systemic therapy is allowed with washout; patients requiring opioids are excluded from naltrexone cohorts.

ClinicalTrials.gov ID: NCT05968690

Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with CLL/SLL who have had at least one NMSC in the past 5 years are randomized to oral nicotinamide 500 mg twice daily vs placebo for 12 months (then all receive nicotinamide in year 2) to prevent new NMSC. Nicotinamide (vitamin B3 amide) replenishes NAD+ to support DNA repair and reduce UV-induced immunosuppression in skin; key exclusions include recent cytotoxic therapy, current nicotinamide/niacin or recent retinoid use, significant drug interactions, and solid-organ transplant on immunosuppression.

ClinicalTrials.gov ID: NCT04844528

A Phase II Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with metastatic uveal melanoma (treatment-naive or previously treated) without prior cemiplimab, bevacizumab, or aflibercept receive cemiplimab (PD-1 inhibitor) plus ziv-aflibercept (VEGF/PlGF trap anti-angiogenic) to test response; a separate cohort includes metastatic cutaneous/mucosal/unknown-primary melanoma progressed after anti–PD-1 (BRAF V600 must have used/declined targeted therapy). Key requirements include ECOG 0–1, measurable disease, adequate organ function, and no active brain mets or significant autoimmune/cardiovascular contraindications.

ClinicalTrials.gov ID: NCT06121180

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic melanoma who have a resectable lesion for tumor procurement and are candidates for anti–PD-1 therapy (including both treatment-naive and those previously treated with PD-1 ± CTLA-4 or BRAF/MEK inhibitors) receive standard pembrolizumab or nivolumab with subsequent addition of AV-MEL-1, an autologous dendritic-cell vaccine loaded with patient-specific tumor antigens plus GM-CSF. The study evaluates safety and preliminary efficacy of combining PD-1 blockade with this personalized DC vaccine intended to enhance T-cell–mediated antitumor immunity.

ClinicalTrials.gov ID: NCT03743298

A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Advanced Melanoma Receiving Post-progression Dual Immune Checkpoint Inhibitor Therapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable/metastatic melanoma that has progressed on prior PD‑1–based therapy receive standard ipilimumab (CTLA‑4 inhibitor) plus nivolumab (PD‑1 inhibitor) combined with image‑guided core biopsy and percutaneous cryoablation of one enlarging lesion between cycles 1 and 2. Allows asymptomatic brain metastases and controlled HIV/HBV/HCV; requires at least one measurable non‑ablated lesion and one lesion amenable to cryoablation.

ClinicalTrials.gov ID: NCT05779423

Phase I Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced solid tumors (safety cohort) or anti–PD-(L)1–refractory melanoma enriched for acral subtype (efficacy cohort), ECOG 0–1, with 1–4 lesions suitable for SBRT. Treatment is concurrent SBRT plus nivolumab and BMS-986253 (anti–IL-8 monoclonal antibody that neutralizes CXCL8 to reduce neutrophil/MDSC trafficking and enhance antitumor immunity).

ClinicalTrials.gov ID: NCT04572451